Bavarian Nordic (OTCMKTS:BVNRY) Stock Crosses Above 50 Day Moving Average - Here's Why

Key Points

• Bavarian Nordic's shares have surpassed their 50-day moving average of $12.18, reaching a high of $12.47 during trading.
• The company reported earnings of $0.23 per share for the last quarter, with a net margin of 21.95% and an anticipated 0.67 EPS for the current fiscal year.
• Bavarian Nordic specializes in developing and commercializing life-saving vaccines, including those for smallpox, monkeypox, rabies, and Ebola.

Shares of Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $12.18 and traded as high as $12.47. Bavarian Nordic shares last traded at $12.47, with a volume of 1,038 shares.

Bavarian Nordic Price Performance

The stock's 50 day moving average price is $12.18 and its two-hundred day moving average price is $10.14. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of 14.33 and a beta of 1.27.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its quarterly earnings data on Friday, August 22nd. The company reported $0.23 earnings per share for the quarter. Bavarian Nordic had a net margin of 21.95% and a return on equity of 12.35%. The business had revenue of $251.14 million during the quarter. As a group, equities research analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.